ClinicalTrials.gg
CompletedNCT04709536Updated Oct 31, 2024

A Study of IBI306 in Participants With Hypercholesterolemia

A Phase 3 interventional study of IBI306 and Placebo in Hypercholesterolemia, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.

Enrollment
18th of 53
306 · median 207
Started
2021
with 6 others
Phase 3
25 of 59
4 open now
Registered
28th of 59
by date
Lead sponsor
4 of 59
Innovent Biologics (Suzhou) Co. Ltd.

Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 18th largest by enrollment of the 53 interventional ones that give a count, is one of 7 that started in 2021, is one of 25 in phase 3, and was the 28th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

This study is designed for multi-center, double-blind, randomized, placebo-controlled phase III trial to evaluate the safety and tolerability of subcutaneous injection of IBI306 in hypercholesterolemia patients.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ≥ 18 to ≤ 75 years of age
  2. Diagnosis of hypercholesterolemia
  3. LDL cholesterol ≥ 70 mg/dl (1.8mmol/L)
  4. Very high or high cardiovascular risk
  5. TG≤500 mg/dL(5.64 mmol/L)

Exclusion criteria

Exclusion criteria

  1. Uncontrolled hypertension
  2. Uncontrolled hyperthyroidism or hypothyroidism
  3. Severe renal dysfunction
  4. Known sensitivity to any of the products to be administered during dosing
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
306 participants (actual)

Study arms

  • Experimental
    IBI306

    IBI306 administered subcutaneously (SC)

    Drug: IBI306

  • Placebo comparator
    Placebo

    administered subcutaneously (SC)

    Drug: Placebo

Interventions

  • DrugIBI306

    Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24

  • DrugPlacebo

    Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24

06

What researchers measure

Primary outcomes

  1. 1. Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at weeks 12

    Time frame: Baseline to week12

Secondary outcomes

  1. The percent of subjects with LDL-C reduction no less than 50% from baseline

    Time frame: Baseline to week24

  2. The percent of subjects with LDL-C<70mg/dL(1.8 mmol/L)

    Time frame: Baseline to week24

  3. The percent change in Lp(a),ApoB, non-HDL-c, ApoB/ApoA1 from baseline

    Time frame: Baseline to week24

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Nov 2021, 9 months.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2021
First posted
Jan 14, 2021
StartActual
Feb 9, 2021
Primary completionActual
Nov 9, 2021
CompletionActual
Jan 28, 2022
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04709536
Responsible party
Sponsor
First posted
Jan 14, 2021
Start date
Feb 9, 2021
Primary completion
Nov 9, 2021
Completion
Jan 28, 2022
Last update
Oct 31, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafolecimab

Start the discussion